GE HealthCare Reports Q3 2026 Beat, Raises Full-Year Guidance & Announces PCS Leadership Transition

Executive Summary

On October 28, 2026, GE HealthCare Technologies Inc. (NASDAQ: GEHC) filed a Current Report on Form 8-K covering Items 2.02 (Results of Operations and Financial Condition), 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), and 9.01 (Financial Statements and Exhibits).

The filing highlights a strong operating performance in Q3 2026 characterized by top- and bottom-line expansion exceeding company targets, an upward revision to full-year 2026 guidance, strategic portfolio expansion via the acquisition of SOFIE Biosciences, and an executive leadership transition in its Patient Care Solutions segment.

---

Key Financial Highlights (Q3 2026)

• Revenue Performance: Total revenue came in at $5,513 million, up 7.2% YoY (organic growth of 6.2%), reflecting broad-based expansion across all segments.
  • Advanced Imaging Solutions (AIS): $3,873 million (+6.1% YoY; +4.5% organic)
  • Pharmaceutical Diagnostics (PDx): $846 million (+13.0% YoY; +13.8% organic)
  • Patient Care Solutions (PCS): $793 million (+8.5% YoY; +8.8% organic)
• Profitability & Margins:
  • Net income attributable to GE HealthCare was $615 million (11.1% margin, +250 bps YoY), compared to $446 million in Q3 2025.
  • Adjusted EBIT was $913 million (16.6% margin, +180 bps YoY), up from $761 million in Q3 2025.
  • Diluted EPS rose 39.1% YoY to $1.36; Adjusted EPS increased 25.1% YoY to $1.34.
• Commercial Momentum: Organic orders climbed 4.0%, achieving a book-to-bill ratio of 1.03x and bringing total backlog to $23.7 billion.
• Cash Flow: Operating cash flow reached $907 million (+53% YoY) and free cash flow stood at $793 million (+64% YoY), both benefiting from a $55 million tariff refund.

---

Upward Revision to Full-Year 2026 Guidance

Management raised expectations across revenue, operating margins, earnings, and cash flow:

Metric	Prior 2026E Guidance	Updated 2026E Guidance
Organic Revenue Growth	3.0% – 4.0%	~4.0%
Adjusted EBIT Margin	15.4% – 15.7% (10–40 bps expansion)	15.5% – 15.7% (20–40 bps expansion)
Adjusted ETR	20.0% – 21.0%	Reaffirmed
Adjusted EPS	$4.80 – $5.00 (+4.6% to +9.0%)	$4.95 – $5.05 (+7.9% to +10.1%)
Free Cash Flow	~$1.6B	$1.6B+

---

Corporate Governance & Executive Leadership Transition (Item 5.02)

• Resignation: On October 22, 2026, Jeannette Bankes notified GE HealthCare of her decision to step down as President and CEO, Patient Care Solutions (PCS), effective November 15, 2026, to take a Chief Executive Officer role at another publicly traded corporation.
• Succession: Neal Sandy, currently Head of PCS Product Strategy and Management and an industry veteran with more than 30 years of healthcare experience, will assume the position of President and CEO of Patient Care Solutions on November 16, 2026.

---

Strategic Developments & Capital Allocation

• M&A Activity: In October 2026, GE HealthCare announced an agreement to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. The acquisition strengthens the company's radiopharmaceutical production and distribution footprint in the U.S., with closing expected in H1 2027.
• Dividend: Declared a quarterly cash dividend of $0.04 per share, representing a 14% increase over the prior quarter.